Clinical trials: Patients With Schizophrenia
The Primary Evaluation is the Change From Baseline at End of Study for CDSS Total Scores., The Secondary Efficacy Evaluations Include: MADRS, PANSS Total Scores and Subscales and Responder Rate; CGI-S and CGI-I Scales.
Efficacy and Safety of Ziprasidone to Treat Depressive Symptoms in Patients With Schizophrenia
This study is going to determine the efficacy, tolerability and safety of ziprasidone in 120 schizophrenic patients with depressive symptoms. The study will be carried out at 2 mental centers in China.
- Conditions
- The Primary Evaluation is the Change From Baseline at End of Study for CDSS Total Scores., The Secondary Efficacy Evaluations Include: MADRS, PANSS Total Scores and Subscales and Responder Rate; CGI-S and CGI-I Scales., Safety Evaluations Include: Laboratory Test Abnormalities; BARS and SAS; Physical Examinations; Vital Signs; Electrocardiogram,Etc., Subjective Well-being Under Neuroleptics Short Form Will be Used in Our Study to Assess the Subjective Side-effects.
- Trial name
- NCT01260116
- Volunteers
- 120 people
- Sponsor
- Wuhan University
Schizophrenia, Schizoaffective Disorder
Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER
Paliperidone ER is a new psychotropic medication for schizophrenia treatment. The studies of 6-week acute treatment and 52-week maintenance treatment showed positive results in patients with schizophrenia and its clinical…
- Trial name
- NCT02075528
- Testing
- Paliperidone ER
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Taipei City Hospital
Schizophrenia Disorders, Treatment Resistant Hallucinations
Cognitive and Metacognitive Evaluation in VR-Based Avatar Therapy for Psychosis
This study aims to evaluate the relationship between cognitive, metacognitive and social cognition variables in patients with psychosis undergoing VR-based Avatar Therapy for the treatment of auditory hallucinations.
- Trial name
- Meta-VR-AVATAR (NCT07091344)
- Testing
- VR-Based Avatar Therapy with Cognitive and Metacognitive Assessments
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundació Sant Joan de Déu
Schizophrenia
A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety, tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients with schizophrenia.
- Trial name
- NCT04712734
- Testing
- Iloperidone
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia, Episodic Memory Deficits
Retrieval Practice and Schizophrenia
When people are tested on a previously learned material, they will later remember it better even when compared to a condition where they can re-study it.
- Trial name
- NCT02108899
- Testing
- Retrieval practice effect using descriptive stories and free-call tests without feedback
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Impaired Insight
Targeted Intervention Study of DTMS on Impaired Insight in Early Psychosis
Impaired insight is a key factor in the conversion of high-risk individuals to schizophrenia, but there is a lack of targeted interventions.
- Trial name
- NCT04513132
- Testing
- active-dTMS
- Where
- China
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Cognitive Impairment
Study of ALTO-101 in Patients With Schizophrenia
This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition.
- Trial name
- NCT06502964
- Testing
- ALTO-101, ALTO-101 Transdermal Delivery System
- Where
- 14 sites in United States
- Volunteers
- 82 people
- Sponsor
- Alto Neuroscience
Schizophrenia
A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot
This study will evaluate the safety, tolerability, efficacy and pharmacokinetics of aripiprazole intramuscular (IM) depot multiple doses every 4 weeks in adult patients with schizophrenia.
- Trial name
- NCT01870999
- Testing
- aripiprazole IM depot, aripiprazole tablets
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia
The purpose of this study is to evaluate the safety and tolerability of Lu AF11167 in patients with schizophrenia following various repeated dosing regimens of Lu AF11167 (alone or as added treatment to risperidone).
- Trial name
- NCT02202213
- Testing
- Lu AF11167
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- H. Lundbeck A/S
Tardive Dyskinesia, Schizophrenia
Extract of Ginkgo Biloba and Tardive Dyskinesia
The purpose of this study is to determine whether Extract of Ginkgo Biloba is effective in the treatment on Tardive dyskinesia
- Trial name
- EGBTD (NCT00672373)
- Testing
- Extract of Ginkgo Biloba (EGb-761 capsules)
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Beijing HuiLongGuan Hospital
Schizophrenia, Schizoaffective Disorder
Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease
The purpose of this study is to evaluate the tolerability and safety of paliperidone ER (extended-release) in doses between 3 milligrams per day and 12 milligrams per day in the treatment of patients with schizophrenia or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- NCT00535145
- Testing
- Treatment as usual (TAU), Paliperidone ER
- Where
- 21 sites in United States
- Volunteers
- 121 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Psychotic Disorders
Serial Comparisons of Abdominal and Neurological MRI Scans
The purpose of this study is to compare abdominal weight gain and fat distribution to changes in brain morphology in people taking antipsychotic medications.
- Trial name
- SCANMRI (NCT02009969)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of British Columbia
Mania, Schizophrenia
Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect
With this observational study we want to examine if the intensity of agitation, the intensity of psychotic symptoms and the presence of sleeping disorder predict the success of the treatment with a atypical antipsychotic after 12…
- Trial name
- UPTAQE (NCT00534222)
- Where
- 6 sites in Netherlands
- Volunteers
- 387 people
- Sponsor
- AstraZeneca
Schizophrenia
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia.
- Trial name
- NCT01235520
- Testing
- RO4917838
- Where
- 121 sites in United States, Argentina and 12 more
- Volunteers
- 595 people
- Sponsor
- Hoffmann-La Roche
Affective Psychosis, Bipolar, Bipolar Disorder
A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety over a 6-week period of paliperidone ER compared with placebo in treating subjects with Bipolar I Disorder who are experiencing a manic or mixed episode while…
- Conditions
- Affective Psychosis, Bipolar, Bipolar Disorder, Mania
- Trial name
- NCT00309686
- Testing
- Paliperidone ER
- Volunteers
- 300 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cannabis Dependence, Marijuana Dependence
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders.
- Trial name
- DCCS (NCT01598896)
- Testing
- Dronabinol, Clonidine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mclean Hospital
Schizophrenia
cTBS on First-episode Drug Naive Patients With Schizophrenia
cTBS is a promising novel intervention, which have strong potentials on moderating disease syndrome, suck as verbal hallucination, and cognitive deficits in schizophrenia, as it has been proved for the treatment of depression.
- Trial name
- NCT05086133
- Testing
- transcranial magnetic stimulation
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Central South University
Schizophrenia, Cognitive Effect on Schizophrenic Patients
Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia
This is a randomized, double-blind, active-controlled, 6 month study designed to evaluate the cognitive effects of treatment with CYP-1020 compared to risperidone.
- Trial name
- CLARITY (NCT01363349)
- Testing
- CYP-1020, Risperidone
- Where
- 39 sites in India, Moldova and 1 more
- Volunteers
- 269 people
- Sponsor
- BioLineRx, Ltd.
Psychosis
The Effect of Psycho-education on Clinical Outcomes Among Patients With a First Episode Psychosis in Central Uganda
Background: Psychotic disorders which the investigators have operationally defined as any of schizophrenia or schizophrenia spectrum disorder, brief psychotic episode, or bipolar affective disorders are severe forms of mental…
- Trial name
- NCT04602585
- Testing
- Psycho-education
- Volunteers
- 80 people
- Sponsor
- Makerere University
Schizophrenia
Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119
This study will consist of 2 parts: Part Ⅰ-in healthy adult subjects, Part Ⅱ-in adult patients with schizophrenia
- Trial name
- NCT06504290
- Testing
- VV119 （in healthy adult subjects）, VV119(in adult patients with schizophrenia)
- Where
- 4 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences